dance therapeutics, LLC

3 mux lane
lloyd harbor, new york 11743

NYS Entity Status
ACTIVE

NYS Filing Date
MAY 13, 2014

NYS DOS ID#
4576143

County
SUFFOLK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - DANCE THERAPEUTICS, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • 7 Frank Lloyd Wright Windows to Go Home
    By EVE M. KAHN - Wednesday Jul 12, 2017

    A newly restored house in Buffalo by Frank Lloyd Wright receives a bountiful stained-glass gift from the University of Victoria in Canada.

    Source: NYT > Home Page
  • New York Today: New York Today: New Subway Clocks
    By JONATHAN WOLFE - Monday Aug 7, 2017

    Monday: Rolling out new subway clocks, the Corkscrew Theater Festival, and National Lighthouse Day.

    Source: NYT > Home Page
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy VC, Deals, & Startups Feed
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York